Overproduction of nitric oxide in cytokine-mediated and septic shock

Journal of the National Cancer Institute

Volumn 84, Issue 11, 1992, Pages 827-831

  Kilbourn, Robert G ^a   Griffith, Owen W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

DRUG MECHANISM; DRUG SCREENING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOTHERAPY; LD 50; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; VASCULAR RESISTANCE;

AMINO ACID OXIDOREDUCTASES; ANIMAL; ARGININE; CYTOKINES; HUMAN; INTERLEUKIN-2; NEOPLASMS; NITRIC OXIDE; NITRIC-OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; SHOCK, SEPTIC;

EID: 0026741759     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.11.827     Document Type: Editorial

References (15)

1. Fisher B, Bauer M, Wickerham DL, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983
2. McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320:525-527, 1989
3. Callahan R, Cropp CS, Merlo GR, et al: Somatic mutations and human breast cancer. A status report. Cancer 69:1582-1588, 1992
4. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
5. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
6. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
7. Soussi T, Caron de Fromental C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952, 1990
8. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
9. Slamon DJ: Expression of the nm23 gene and breast cancer prognosis. J Natl Cancer Inst 83:229-231, 1991
10. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
11. Callahan R, Campbell G: Mutations in human breast cancer: An overview. J Natl Cancer Inst 81:1780-1786, 1989
12. Cattoretti G, Rilke F, Andreola S, et al: p53 expression in breast cancer. Int J Cancer 41:178-183, 1988
13. Ostrowski JL, Sawan A, Henry L, et al: p53 expression in human breast cancer related to survival and prognostic factors: An immuno-histochemical study. J Pathol 164:75-81, 1991
14. Davidoff AM, Iglehart JD, Marks JR.: Immune response to p53 is dependent upon p53/hsp70 complexes in breast cancers. Proc Natl Acad Sci USA. In press
15. Allred DC, Clark GM, Brown RW, et al: Mutation of p53 is associated with increased proliferation and early recurrence in node-negative breast cancer. Proc Am Soc Clin Oncol. In press